Can Dogs Become the First Regulated Longevity Market?
Use canine lifespan-extension trials as a regulatory test case for longevity medicine. The piece keeps the focus on evidence, commercial logic, and what would make the claim testable.
Autophagy Is Becoming a Drug Target. The Hard Part Is Measuring It
Autophagy is central to aging biology, but proving target engagement and clinical benefit in humans remains difficult. The piece keeps the focus on evidence, commercial logic, and what would make the claim testable.
Resilience Endpoints: Why Recovery May Matter More Than Biological Age
Vaccine response, post-surgery recovery, infection recovery, exercise adaptation, and stress-response tests as practical geroscience endpoints. The piece keeps the focus on evidence, commercial logic, and what would make the claim testable.
The Data-Moat Problem: When Longitudinal Health Data Is Valuable – and When It Isn’t
Not all data is a moat; standardized, repeated, outcome-linked data is. The piece keeps the focus on evidence, commercial logic, and what would make the claim testable.
Why Women’s Midlife Health Is Becoming a Longevity-Investing Thesis
Menopause, ovarian aging, cardiometabolic risk, bone, brain, and care-delivery models create a bridge between longevity and women’s health. The piece keeps the focus on evidence, commercial logic, and what would make the claim testable.
The Microbiome Became a Hallmark of Aging. Now Comes the Hard Part
Dysbiosis sounds compelling, but causality, intervention design, individual variability, and clinical usefulness remain difficult. The piece keeps the focus on evidence, commercial logic, and what would make the claim testable.
Why Longevity Clinics Need Outcomes Registries, Not Just Test Menus
Clinics need longitudinal outcome tracking, adverse-event capture, standardized reporting, and transparent follow-up. The piece keeps the focus on evidence, commercial logic, and what would make the claim testable.
Wearables as Aging Biomarkers: Useful Signal or Lifestyle Noise?
Evaluate heart-rate variability, sleep, gait, activity, recovery, arrhythmia detection, and the limits of consumer-device data as aging biomarkers. The piece keeps the focus on evidence, commercial logic, and what would make the claim testable.
Why Negative Longevity Trials Matter More Than the Field Admits
Failed or mixed trials define endpoints, populations, dosing, mechanisms, and claim boundaries. The piece keeps the focus on evidence, commercial logic, and what would make the claim testable.
Rapamycin’s Longevity Case: Strong in Animals, Still Unsettled in Humans
A measured piece on mTOR, off-label enthusiasm, human evidence, side effects, dosing, and why rapamycin remains both important and unresolved. The piece keeps the focus on evidence, commercial logic, and what would make the claim testable.